Fig. 1 · Structure

Documents & Downloads

Apaziquone

Cat. No. A12406 CAS 114560-48-4
Apaziquone is an indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities.

This product is currently unavailable.

Ask us for lead time and price.

Inquire about this product

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Apaziquone Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Apaziquone from 2 published references. In vitro models include RT112 human bladder carcinoma cell lines; AMOS III. In vivo models include male immune-compromised NOD/SCID/CRL#394 mice.

Apaziquone In Vitro Studies

Apaziquone exposure for 1 h yielded MTT growth inhibition IC50 values of 1.11 ± 0.09 µM in RT112 human bladder carcinoma cells. In EJ138 human bladder carcinoma cells, the same exposure duration yielded an IC50 of 0.915 ± 0.291 µM. In AMOS III, exposure to Apaziquone for 48 hours yielded a reported LD50 of 500nM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Apaziquone growth inhibition in RT112 bladder carcinoma cells

Cell-based study · RT112 human bladder carcinoma cell lines [1]

RT112 human bladder carcinoma cells were exposed to Apaziquone for 1 h. Growth inhibition measured using the MTT assay yielded an IC50 of 1.11 ± 0.09 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
growth inhibition determination using the MTT assayIC50 1.11 ± 0.09 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10–0.196 µM
Exposure duration
Cells were exposed to apaziquone for 1 h
Method
media containing a range of apaziquone concentrations
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Apaziquone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell lines and chemosensitivity studies (S8, S9, S11, S12, S13, S14, S16); Results > Response of EJ138 and RT112 cells to apaziquone (S36)

growth inhibition determination using the MTT assay: growth inhibition determination using the MTT assay; comparator: control cells — Materials and methods > Cell lines and chemosensitivity studies (S13); Results > Response of EJ138 and RT112 cells to apaziquone (S36)

Apaziquone response in AMOS III

Cell-based study · AMOS III [2]

AMOS III was exposed to Apaziquone-containing media for 48 hours. The reported LD50 was 500nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LD50LD50 500nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
5nM to100μM
Exposure duration
48 hours
Method
media containing apaziquone
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: Apaziquone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > In vitro LD50 measurements for Apaziquone (S15, S17, S18); Results > Effect of apaziquone on oral cancer cells (S55)

LD50: LD50 — Materials and Methods > In vitro LD50 measurements for Apaziquone (S15); Results > Effect of apaziquone on oral cancer cells (S55)

Apaziquone growth inhibition in EJ138 bladder carcinoma cells

Cell-based study · EJ138 human bladder carcinoma cell lines [1]

EJ138 human bladder carcinoma cells were exposed to Apaziquone for 1 h. Growth inhibition measured using the MTT assay yielded an IC50 of 0.915 ± 0.291 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
growth inhibition determination using the MTT assayIC50 0.915 ± 0.291 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10–0.196 µM
Exposure duration
Cells were exposed to apaziquone for 1 h
Method
media containing a range of apaziquone concentrations
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Apaziquone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell lines and chemosensitivity studies (S8, S9, S11, S12, S13, S14, S16); Results > Response of EJ138 and RT112 cells to apaziquone (S36)

growth inhibition determination using the MTT assay: growth inhibition determination using the MTT assay; comparator: control cells — Materials and methods > Cell lines and chemosensitivity studies (S13); Results > Response of EJ138 and RT112 cells to apaziquone (S36)

Apaziquone In Vivo Studies

Male immune-compromised NOD/SCID/CRL#394 mice received Apaziquone by intraperitoneal injections at 0.1 mg/kg body weight weekly for 6 weeks. Apaziquone significantly delayed tumor growth in the comparison between treated and untreated groups. [2]

Apaziquone delays tumor growth in mice

Animal study · male immune-compromised NOD/SCID/CRL#394 mice [2]

Male immune-compromised NOD/SCID/CRL#394 mice received Apaziquone by intraperitoneal injections at 0.1 mg/kg body weight weekly for 6 weeks. Apaziquone significantly delayed tumor growth in the comparison between treated and untreated groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mean tumor volumemean tumor volume 220.05mm3[2]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
weekly for 6 weeks
Vehicle
0.1% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Apaziquone 0.1 mg/kg body weightuntreated vehicle control groupmean tumor volume was 220.05mm3; mean tumor volume of 376.18 mm3; apaziquone treatment delayed tumor growth significantly (p value<0.001, paired two-tailed Student's t-test between the treated and untreated groups; Fig 5B and 5C)[2]
Apaziquone 0.1 mg/kg body weight
Model: male immune-compromised NOD/SCID/CRL#394 mice
Methods and source locations

Compound reported in the paper: Apaziquone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > In vivo antitumor activity of Apaziquone in xenograft model of human oral squamous cell carcinoma (S33, S35); Results > In vivo anti-tumor activity of apaziquone (S66, S67); Fig 5 legend (S88)

mean tumor volume: mean tumor volume; comparator: untreated vehicle control group — Results > In vivo anti-tumor activity of apaziquone (S66, S67)

Apaziquone 0.1 mg/kg body weight · Materials and Methods > In vivo antitumor activity of Apaziquone in xenograft model of human oral squamous cell carcinoma (S35); Results > In vivo anti-tumor activity of apaziquone (S66, S67); Fig 5 legend (S88)

Specifications

Manufacturer Adooq Bioscience
CAS Number 114560-48-4
Formula C15H16N2O4
Molecular Weight 288.3
SMILES
CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)/C=C/CO

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Apaziquone Research References

  1. [1] Phillips RM, Loadman PM, Reddy G. Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer. Cancer Chemother Pharmacol (2019). PMID: 30868237 DOI: 10.1007/s00280-019-03812-7 Source material
  2. [2] Srivastava G, Somasundaram RT, Walfish PG, et al. Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy. PLoS One (2015). PMID: 26208303 DOI: 10.1371/journal.pone.0133735 Source material

Added to your cart

View Cart Checkout
Loading...